Devanand, D. P., Mintzer, Jacobo, Schultz, Susan K., Andrews, Howard F., Sultzer, David L., de la Pena, Danilo, Gupta, Sanjay, Colon, Sylvia, Schimming, Corbett, Pelton, Gregory H., Levin, Bruce

Background: Among patients with Alzheimer’s disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.; Methods: Patients with Alzheimer’s disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a […]

Howard, Robert, McShane, Rupert, Lindesay, James, Ritchie, Craig, Baldwin, Ashley, Barber, Robert, Burns, Alistair, Dening, Tom, Findlay, David, Holmes, Clive, Hughes, Alan, Jacoby, Robin, Jones, Rob, Jones, Roy, McKeith, Ian, Macharouthu, Ajay, O'Brien, John, Passmore, Peter, Sheehan, Bart, Juszczak, Edmund, Katona, Cornelius, Hills, Robert, Knapp, Martin, Ballard, Clive, Brown, Richard, Banerjee, Sube, Onions, Caroline, Griffin, Mary, Adams, Jessica, Gray, Richard, Johnson, Tony, Bentham, Peter, Phillips, Patrick

Background: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer’s disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.; Methods: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer’s […]

Green, Robert C., Roberts, J. Scott, Cupples, L. Adrienne, Relkin, Norman R., Whitehouse, Peter J., Brown, Tamsen, Eckert, Susan LaRusse, Butson, Melissa, Sadovnick, A. Dessa, Quaid, Kimberly A., Chen, Clara, Cook-Deegan, Robert, Farrer, Lindsay A.

Background: The apolipoprotein E (APOE) genotype provides information on the risk of Alzheimer’s disease, but the genotyping of patients and their family members has been discouraged. We examined the effect of genotype disclosure in a prospective, randomized, controlled trial.; Methods: We randomly assigned 162 asymptomatic adults who had a parent with Alzheimer’s disease to receive […]

Salloway, Stephen, Sperling, Reisa, Fox, Nick C., Blennow, Kaj, Klunk, William, Raskind, Murray, Sabbagh, Marwan, Honig, Lawrence S., Porsteinsson, Anton P., Ferris, Steven, Reichert, Marcel, Ketter, Nzeera, Nejadnik, Bijan, Guenzler, Volkmar, Miloslavsky, Maja, Wang, Daniel, Lu, Yuan, Lull, Julia, Tudor, Iulia Cristina, Liu, Enchi, Grundman, Michael, Yuen, Eric, Black, Ronald, Brashear, H. Robert

Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]

Doody, Rachelle S., Raman, Rema, Farlow, Martin, Iwatsubo, Takeshi, Vellas, Bruno, Joffe, Steven, Kieburtz, Karl, He, Feng, Sun, Xiaoying, Thomas, Ronald G., Aisen, Paul S, Siemers, Eric, Sethuraman, Gopalan, Mohs, Richard

Background: Alzheimer’s disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer’s disease.; Methods: We conducted a double-blind, placebo-controlled trial in which 1537 patients […]